According to Biotab Nutraceuticals chief marketing officer Robert Wilhovsky, there is seasonality within sleep aids. Biotab fielded the No. 3 sleep aid Alteril in food, drug and mass (without Walmart) with dollar growth of more than 126% for the 12 weeks ended April 15, according to SymphonyIRI Group data. Drug Store News caught up with Wilhovsky to talk about how Biotab approaches the overall sleep category, and how the company helps drive its sleep aid solution through key selling periods.
One subcategory that has really jolted the sales-per-square-inch across analgesic sets is sleep aids. Sales of sleeping remedies, including both liquids and tablets, were up 51.2% to $408 million for the 52 weeks ended Aug. 11 across U.S. multi-outlets, according to IRI data.
Results from a new survey released Monday of 5,256 PatientsLikeMe members who live day to day with life-changing conditions found that nearly one-third of respondents never (5%) or rarely (25%) get a good night’s sleep.
With the launch of Procter & Gamble's ZzzQuil, a relatively quiet sleep category has exploded with energy this year. A lot of that has to do with the $121.1 million in sales that ZzzQuil — both tablet and liquid formulations — has generated this year.
Neuro health drinks are comprised of six different formulated drinks: Sonic, Passion, Trim, Daily, Bliss and Sleep, with each offering a different benefit — boosting mental performance, reducing stress, promoting restful sleep and more.
Retailers are awakening to the possibility that their sleep aids — typically merchandised near the floor level of a set synergistically near tablet pain relievers — may deserve a placement closer to eye level.
People who suffer from sleep disturbances are at major risk for obesity, diabetes and coronary artery disease, according to new research from the Perelman School of Medicine at the University of Pennsylvania.